검색어: mf (영어 - 크로아티아어)

(mf)
(mt)

myelofibrosis (mf)
mijelofibroza (mf)

frequency category for mf patients
kategorija učestalosti za bolesnike s mf-om

tuberculosis has been reported in patients receiving jakavi for mf.
u bolesnika koji primaju jakavi zbog mf-a zabilježena je tuberkuloza.

mf patients exhibit dysregulated jak signalling regardless of jak2v617f mutation status.
bolesnici s mf-om pokazuju disreguliranu jak signalizaciju bez obzira na status mutacije jak2v617f.

mf patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time.
bolesnici s mf-om nisu postali refraktorni na farmakodinamičke učinke liječenja ruksolitinibom tijekom vremena.

the mean volume of distribution at steady state is approximately 75 litres in mf and pv patients.
srednji volumen distribucije u stanju dinamičke ravnoteže je približno 75 litara u bolesnika s mf-om i pv-om.

progressive multifocal leukoencephalopathy (pml) has been reported with jakavi treatment for mf.
progresivna multifokalna leukoencefalopatija (pml) zabilježena je uz liječenje jakavijem za mf.

following interruption or discontinuation of jakavi, symptoms of mf may return over a period of approximately one week.
nakon privremenog ili trajnog prekida uzimanja jakavija simptomi mf-a mogu se vratiti tijekom razdoblja od otprilike tjedan dana.

in the phase 3 clinical studies in mf, in patients who developed grade 3 or 4 neutropenia, the median time to onset was 12 weeks.
u kliničkim ispitivanjima mf-a faze 3, u bolesnika koji su razvili neutropeniju stupnja 3 ili 4, medijan vremena do nastupa bio je 12 tjedana.

in phase 3 clinical studies in mf, neither ctcae grade 3 or 4 hypercholesterolaemia, raised aspartate aminotransferase nor ctcae grade 4 raised alanine aminotransferase were observed.
u kliničkim ispitivanjima mf-a faze 3 nisu bili uočeni ni hiperkolesterolemija stupnja 3 ili 4 prema ctcae-u, ni povišenje aspartat aminotransferaze, ni povišenje alanin aminotransferaze stupnja 4 prema ctcae-u.

baseline elevations in inflammatory markers associated with constitutional symptoms such as tnfα, il-6 and crp in subjects with mf were decreased following treatment with ruxolitinib.
početna povišenja upalnih markera povezanih s konstitucionalnim simptomima kao što su tnfα, il-6 i crp u ispitanika s mf-om bila su smanjena nakon liječenja ruksolitinibom.

a single dose of 15 mg is recommended for mf patients with platelet count between 100,000/mm3 and 200,000/mm3.
jednokratna doza od 15 mg se preporučuje za bolesnike s mf-om s brojem trombocita između 100 000/mm3 i 200 000/mm3.